We can do better: a fresh look at echinocandin dosing
Open Access
- 1 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (suppl_1) , i44-i50
Abstract
First-line antifungal therapies are limited to azoles, polyenes and echinocandins, the former two of which are associated with high occurrences of severe treatment-emergent adverse events or frequent drug interactions. Among antifungals, echinocandins present a unique value proposition given their lower rates of toxic events as compared with azoles and polyenes. However, with the emergence of echinocandin-resistant Candida species and the fact that a pharmacometric approach to the development of anti-infective agents was not a mainstream practice at the time these agents were developed, we question whether echinocandins are being dosed optimally. This review presents pharmacokinetic/pharmacodynamic (PK/PD) evaluations for approved echinocandins (anidulafungin, caspofungin and micafungin) and rezafungin (previously CD101), an investigational agent. PK/PD-optimized regimens were evaluated to extend the utility of approved echinocandins when treating patients with resistant isolates. Although the benefits of these regimens were apparent, it was also clear that anidulafungin and micafungin, regardless of dosing adjustments, are unlikely to provide therapeutic exposures sufficient to treat highly resistant isolates. Day 1 probabilities of PK/PD target attainment of 5.2% and 85.1%, respectively, were achieved at the C. glabrata MIC90 (0.12 mg/L) and MIC97 (0.06 mg/L) values, respectively, for these agents. However, evaluations of rezafungin demonstrated high probabilities of target attainment over 4 weeks of therapy (100%) after administration of a single-dose regimen at the MIC90 of 0.06 mg/L. This signals that although existing therapies are not optimal to treat resistant organisms, more potent new echinocandins (relative to achievable drug exposures) may be on the horizon.Keywords
This publication has 34 references indexed in Scilit:
- In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in HumansClinical Infectious Diseases, 2012
- Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese PeopleAntimicrobial Agents and Chemotherapy, 2011
- Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI TrialAntimicrobial Agents and Chemotherapy, 2011
- Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and MicafunginJournal of Clinical Microbiology, 2011
- FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based SurveillanceAntimicrobial Agents and Chemotherapy, 2010
- Breakthrough Invasive Candidiasis in Patients on MicafunginJournal of Clinical Microbiology, 2010
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2008
- Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive CandidiasisClinical Infectious Diseases, 2007
- Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent NeutropeniaAntimicrobial Agents and Chemotherapy, 2007